[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-342232-105":59,"doc-detail-342232-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ssmutpa-single-sample-mutation-based-pathway-analysis-approach-for-cancer-precision-medicine","ssMutPA - single-sample mutation-based pathway analysis approach for cancer precision medicine","","Single-sample pathway enrichment analysis helps identify cancer subtypes and pathway biomarkers to support precision medicine, yet existing methods largely rely on gene expression changes and overlook somatic mutations. This study introduces ssMutPA, integrating somatic mutation data with a protein–protein interaction network to infer individualized pathway activities via ssMutPES. Applications to 33 TCGA cancer cohorts stratified patients by prognosis and revealed cross-cancer pathways as potential biomarkers. ssMutPA also supported melanoma subgroup identification for immunotherapy benefit.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ssmutpa-single-sample-mutation-based-pathway-analysis-approach-for-cancer-precision-medicine/342232/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ssmutpa-single-sample-mutation-based-pathway-analysis-approach-for-cancer-precision-medicine/342232.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What limitation of existing single-sample pathway methods does ssMutPA address?","Question",{"text":112,"@type":113},"It targets the limitation that many approaches focus on gene expression changes and neglect somatic mutations, which are crucial for cancer development.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does ssMutPA estimate individualized pathway activities?",{"text":117,"@type":113},"It integrates somatic mutation data with a protein–protein interaction network, uses local and global weighted strategies to assess mutation effects by network topology, and computes a single-sample mutation-based pathway enrichment score (ssMutPES).",{"name":119,"@type":110,"acceptedAnswer":120},"What results were observed when ssMutPA was applied to cancer and melanoma cohorts?",{"text":121,"@type":113},"Across 33 TCGA cancer cohorts, ssMutPES enabled patient stratification with significantly different prognoses and highlighted characteristic cross-cancer pathways. In two melanoma immunotherapy cohorts, ssMutPA identified a patient subgroup likely to benefit from therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},342232,1791102278,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","GigaScience, 2024, 13, 1–13  \nDOI: 10.1093/gigascience/giae105  \nTechnical Note  \nssMutPA: single-sample mutation-based pathway analysis approach for cancer precision medicine  \nYalan He †, Jiyin Lai †, Qian Wang†, Bingyue Pan  , Siyuan Li  , Xilong Zhao  , Ziyi Wang , Yongbao Zhang  , Yujie Tang ,  \nand Junwei Han  *  \nCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China  \n∗ Correspondence address. Junwei Han, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China. E-mail:  \n[hanjunwei@ems.hrbmu.edu.cn](hanjunwei@ems.hrbmu.edu.cn)  \n†The authors should be regarded as joint first authors.  \nAbstract  \nBackground: Single-sample pathway enrichment analysis is an effective approach for identifying cancer subtypes and pathway biomarkers, facilitating the development of precision medicine. However, the existing approaches focused on investigating the changes in gene expression levels but neglected somatic mutations, which play a crucial role in cancer development.  \nFindings: In this study, we proposed a novel single-sample mutation-based pathway analysis approach (ssMutPA) to infer individualized pathway activities by integrating somatic mutation data and the protein–protein interaction network. For each sample, ssMutPA first uses local and global weighted strategies to evaluate the effects of genes from mutations according to the network topology and then calculates a single-sample mutation-based pathway enrichment score (ssMutPES) to reflect the accumulated effect of mutations of each pathway. To illustrate the performance ofssMutPA, we applied it to 33 cancer cohorts from The Cancer Genome Atlas database and revealed patient stratification with significantly different prognosis in each cancer type based on the ssMutPES profiles. We also found that the identified characteristic pathways with high overlap across different cancers could be used as potential prognosis biomarkers. Moreover, we applied ssMutPA to 2 melanoma cohorts with immunotherapy and identified a subgroup of patients who may benefit from therapy.  \nConclusions: We provided evidence that ssMutPA could infer mutation-based individualized pathway activity profiles and complement the current individualized pathway analysis approaches focused on gene expression data, which may offer the potential for the development of precision medicine. ssMutPA is available at [https://CRAN.R-project.org/package=ssMutPA](https://CRAN.R-project.org/package=ssMutPA).  \nGraphical abstract  \nKeywords: somatic mutation, network topology, single-sample pathway analysis, cancer subtypes, precision medicine  \nBackground  \nOver the past decades, gene signatures derived from transcriptomics data have been recognized in multiple cancers [1–5] . However, their clinical application has been hindered by low reproducibility and small overlap [6–8] . Recently, many studies have proved that cancers are essentially caused by disturbances in the complex regulatory relationships among multiple functional genes, suggesting the need to convert gene expression data into pathway-level activity values for further studies [9 , 10] .  \nPathway enrichment analysis (PEA) is currently the most popular method to interpret transcriptomics data using knowledge of  \ngene sets or biological pathways. Thus, more and more PEA algorithms have been proposed for identifying biomarkers and cancer subtypes, such as gene set enrichment analysis (GSEA) [11], signaling pathway impact analysis (SPIA) [12], and CTpathway [13] . While these methods converted traditional gene expression data into pathway-level analysis and explored the dysregulated pathways between the 2 phenotypes, their effectiveness relied on a large number of sample data. More importantly, they ignore individualized patient information on pathways. To overcome these limitations, individualized pathway activity calculation methods and tools have been evolved, such as single-","cbCaipRDtqVgyDsq","https://ap.wps.com/l/cbCaipRDtqVgyDsq","pdf",2681277,13,"English","# Abstract\n## Background\n## Findings\n## Conclusions\n# Background\n## Pathway enrichment analysis (PEA)\n## Individualized pathway activity methods","[{\"question\":\"What limitation of existing single-sample pathway methods does ssMutPA address?\",\"answer\":\"It targets the limitation that many approaches focus on gene expression changes and neglect somatic mutations, which are crucial for cancer development.\"},{\"question\":\"How does ssMutPA estimate individualized pathway activities?\",\"answer\":\"It integrates somatic mutation data with a protein–protein interaction network, uses local and global weighted strategies to assess mutation effects by network topology, and computes a single-sample mutation-based pathway enrichment score (ssMutPES).\"},{\"question\":\"What results were observed when ssMutPA was applied to cancer and melanoma cohorts?\",\"answer\":\"Across 33 TCGA cancer cohorts, ssMutPES enabled patient stratification with significantly different prognoses and highlighted characteristic cross-cancer pathways. In two melanoma immunotherapy cohorts, ssMutPA identified a patient subgroup likely to benefit from therapy.\"}]","ssMutPA - single-sample mutation-based pathway analysis approach for cancer precision medicine | PDF",1790045861,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6259dcab7f4e42f6cdb9b5422ac509f0.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96a0549571a6ccafa15f7d39b3749d0f.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d956fe53f626270dc7b75c55862a933.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63e73c2262fd59d6ecaee0097359b1e3.webp",980,1287]